

22. A pharmaceutical composition according to claim 21 wherein the active principle is dronedarone hydrochloride.

REMARKS

The specification is amended at page 1 to add a title, and at page 17 to correct an obvious typographical error.

The title is taken from paragraph 1 at page 1, and the error at page 17 is clearly obvious from the context. Thus, given the molecular weights of dronedarone (556.38) and dronedarone hydrochloride (592.38), it is obvious that 213 mg of the hydrochloride corresponds to 200 mg (and not 400 mg) of the free base.

Claims 1-13 are amended to put them in a format consistent with U.S. practice, and/or to eliminate multiple dependencies, and/or to modify dependencies as appropriate.

New claims 14-22 are added. Support for these claims is found as follows.

New claim 14 combines original claims 2 and 3 in Markush format and original claims 2 and 3 as now amended are directed to the preferred species as claimed by original claim 4.

New claim 15 is directed to the subject matter of original claim 6 as dependent from original claims 2 and 3.

New claim 16 is directed to the subject matter of original claim 7 as dependent from original claims 2 and 4.

New claim 17 is directed to the subject matter of original claim 10 as dependent from original claims 2 and 3.

New claim 18 is directed to the subject matter of original claim 10 as dependent from original claims 2, 3 and 7.


New claim 19 is directed to the subject matter of original claim 10 as dependent from original claims 2, 4 and 7.

New claim 20 is directed to the subject matter of original claim 13 as dependent from original claims 2 and 3.

New claim 21 is directed to the subject matter of original claim 13 as dependent from original claims 2, 3 and 7.

Date:

Date: December 22, 1999


Paul E. Dupont
Reg. No. 27,438

Paul E. Dupont
Reg. No. 27,438

[illegible]